3 Health Care Stocks Pushing Sector Growth

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 42 points (-0.3%) at 15,847 as of Thursday, Dec. 5, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 971 issues advancing vs. 1,916 declining with 131 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.4%. Top gainers within the sector include Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.0%, and Covidien ( COV), up 0.7%. On the negative front, top decliners within the sector include Cigna ( CI), down 1.4%, HCA Holdings ( HCA), down 1.0%, UnitedHealth Group ( UNH), down 0.9%, WellPoint ( WLP), down 0.7% and Biogen Idec ( BIIB), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Hospira ( HSP) is one of the companies pushing the Health Care sector higher today. As of noon trading, Hospira is up $1.10 (2.7%) to $41.31 on heavy volume. Thus far, 1.3 million shares of Hospira exchanged hands as compared to its average daily volume of 765,400 shares. The stock has ranged in price between $39.85-$42.43 after having opened the day at $39.85 as compared to the previous trading day's close of $40.21.

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. Hospira has a market cap of $6.6 billion and is part of the drugs industry. Shares are up 28.7% year to date as of the close of trading on Wednesday. Currently there are no analysts that rate Hospira a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Hospira Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Novo Nordisk A/S ( NVO) is up $2.34 (1.3%) to $178.90 on average volume. Thus far, 131,308 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 287,400 shares. The stock has ranged in price between $178.71-$179.72 after having opened the day at $179.16 as compared to the previous trading day's close of $176.56.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $98.7 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 8.2% year to date as of the close of trading on Wednesday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is up $5.64 (3.5%) to $165.71 on average volume. Thus far, 1.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $162.26-$165.88 after having opened the day at $163.32 as compared to the previous trading day's close of $160.07.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $65.9 billion and is part of the drugs industry. The company has a P/E ratio of 46.0, above the S&P 500 P/E ratio of 17.7. Shares are up 103.8% year to date as of the close of trading on Wednesday. Currently there are 19 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Stocks Turn Lower as 10-Year Yield Hits 3%

Stocks Turn Lower as 10-Year Yield Hits 3%

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Tuesday's Market Movers: CAT, UTX, KO, MMM

Tuesday's Market Movers: CAT, UTX, KO, MMM

Wall Street Is Totally Forgetting Apple Will Be Giving Away Tons of Cash in 2018

Wall Street Is Totally Forgetting Apple Will Be Giving Away Tons of Cash in 2018

Vivendi Slides After Reports Vincent Bollore Questioned in Corruption Probe

Vivendi Slides After Reports Vincent Bollore Questioned in Corruption Probe